Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Procept Biorobotics Corp (PRCT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: PRCT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -42.08% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.29B USD | Price to earnings Ratio - | 1Y Target Price 93.86 |
Price to earnings Ratio - | 1Y Target Price 93.86 | ||
Volume (30-day avg) 1024845 | Beta 1.05 | 52 Weeks Range 45.56 - 103.81 | Updated Date 04/1/2025 |
52 Weeks Range 45.56 - 103.81 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.75 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -40.72% | Operating Margin (TTM) -28.89% |
Management Effectiveness
Return on Assets (TTM) -12.87% | Return on Equity (TTM) -26.77% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2939714275 | Price to Sales(TTM) 14.67 |
Enterprise Value 2939714275 | Price to Sales(TTM) 14.67 | ||
Enterprise Value to Revenue 13.09 | Enterprise Value to EBITDA -24.58 | Shares Outstanding 54818700 | Shares Floating 52527278 |
Shares Outstanding 54818700 | Shares Floating 52527278 | ||
Percent Insiders 4.65 | Percent Institutions 93.15 |
Analyst Ratings
Rating 4.4 | Target Price 102.75 | Buy 2 | Strong Buy 6 |
Buy 2 | Strong Buy 6 | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Procept Biorobotics Corp
Company Overview
History and Background
Procept BioRobotics Corp. is a surgical robotics company focused on advancing patient care by developing, manufacturing, and marketing minimally invasive surgical solutions to treat lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). The company was founded in 2008 and its primary product is the AquaBeam Robotic System.
Core Business Areas
- Surgical Robotics: Development and commercialization of the AquaBeam Robotic System for the treatment of BPH.
Leadership and Structure
Vince Fajardo is the Chief Executive Officer. The company has a board of directors overseeing its operations.
Top Products and Market Share
Key Offerings
- AquaBeam Robotic System: AquaBeam is a minimally invasive surgical system that uses a robotically controlled, heat-free waterjet to resect prostate tissue. Market share is growing, but still relatively small compared to established TURP and laser technologies. Competitors include Boston Scientific (laser therapies), Teleflex (Rezu016bm), and Olympus (TURP instruments). Based on 2023 financial statements, Aquabeam generates over 90% of the company's revenue.
Market Dynamics
Industry Overview
The BPH treatment market is large and growing, driven by an aging population and increasing awareness of treatment options. The market includes traditional surgical procedures (TURP), laser therapies, minimally invasive surgical therapies (MISTs), and drug treatments.
Positioning
Procept BioRobotics is positioned as a provider of advanced surgical robotics for BPH treatment, offering a minimally invasive alternative to traditional surgery with potentially improved patient outcomes and reduced recovery times. The company differentiates itself with its Aquablation technology.
Total Addressable Market (TAM)
The global BPH surgical device market is estimated to be worth billions of dollars. Procept Biorobotics Corp is aiming to capture a significant share of this market with the Aquabeam system.
Upturn SWOT Analysis
Strengths
- Innovative Aquablation technology
- Minimally invasive procedure
- Potential for improved patient outcomes
- Robotic precision
- Growing clinical evidence base
Weaknesses
- Limited market share compared to established therapies
- High capital cost of the AquaBeam system
- Need for physician training
- Relatively new technology requiring further market acceptance
Opportunities
- Increasing adoption of MISTs for BPH treatment
- Expansion into new geographic markets
- Development of new applications for the AquaBeam technology
- Partnerships with hospitals and urology practices
- Growing awareness of Aquablation benefits
Threats
- Competition from established BPH therapies
- Reimbursement pressures from healthcare providers
- Technological advancements by competitors
- Potential for adverse events associated with the procedure
- Economic downturn impacting hospital capital spending
Competitors and Market Share
Key Competitors
- BSX
- TFX
- OCPNY
Competitive Landscape
Procept Biorobotics faces strong competition from established players in the BPH treatment market. Its competitive advantage lies in its innovative Aquablation technology, but it needs to overcome the challenges of market adoption and reimbursement.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Procept Biorobotics has experienced strong revenue growth in recent years, driven by increasing adoption of the AquaBeam system.
Future Projections: Analysts expect continued revenue growth in the coming years as the company expands its sales force and penetrates new markets.
Recent Initiatives: Recent initiatives include expanding the sales team, increasing marketing efforts, and conducting clinical trials to support the use of AquaBeam.
Summary
Procept BioRobotics shows high growth potential due to its innovative Aquablation technology but is currently operating at a loss. Its strengths lie in its minimally invasive procedure and growing clinical data. However, it faces challenges in gaining market share against established therapies and managing high costs. Investors should monitor its path to profitability and competitive pressures.
Similar Companies
ABT
Abbott Laboratories
ABT
Abbott Laboratories
BSX
Boston Scientific Corp
BSX
Boston Scientific Corp
ISRG
Intuitive Surgical Inc
ISRG
Intuitive Surgical Inc
Sources and Disclaimers
Data Sources:
- Company filings (SEC), Investor Relations Materials, Market Research Reports, Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Procept Biorobotics Corp
Exchange NASDAQ | Headquaters San Jose, CA, United States | ||
IPO Launch date 2021-09-15 | President, CEO & Director Dr. Reza Zadno Ph.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 756 | |
Full time employees 756 | |||
PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. It also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.